Diagnostic value of epicardial adipose tissue thickness combined with serum ADAM10 and STIM1 for coronary heart disease

doi:10.11958/20250781

Abstract

Abstract:

Objective To explore the diagnostic value of epicardial adipose tissue (EAT) thickness combined with serum disintegrin metalloprotease 10 (ADAM10) and stromal interaction molecule 1 (STIM1) in coronary heart disease (CHD). Methods A total of 119 CHD patients were included as the study group, and 100 non-CHD patients in the same period were selected as the control group. The clinical data of the patients were collected. Serum ADAM10 and STIM1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Color Doppler ultrasonography was applied to detect EAT thickness. Multivariate Logistic regression was used to analyze influencing factors of CHD occurrence. The diagnostic value of EAT thickness combined with serum ADAM10 and STIM1 levels in the diagnosis of CHD was analyzed by subject work characteristics (ROC) curves. Results The levels of triglycerides, low-density lipoprotein cholesterol (LDL-C), EAT thickness, serum ADAM10 and STIM1 were higher in the study group than those in the control group (P<0.05). Logistic regression analysis showed that elevated EAT thickness, serum ADAM10, STIM1, triglyceride and LDL-C levels were independent risk factors for the occurrence of CHD (P<0.05). ROC curve analysis showed that the area under the curve of EAT thickness combined with serum ADAM10 and STIM1 for the diagnosis of CHD [0.864 (95%CI: 0.811-0.907)] was higher than that of their respective individual diagnoses [0.801 (95%CI: 0.741-0.851), 0.750 (95%CI: 0.687-0.806), respectively, 0.799 (95%CI: 0.740-0.850)], and the sensitivity and specificity of the combined diagnosis were 82.35% and 83.00%, respectively. Conclusion EAT thickness, serum ADAM10 and STIM1 levels are obviously elevated in CHD patients, and the combination of the three tests has a high diagnostic value for CHD.

Key words: coronary disease, epicardial adipose tissue thickness, a disintegrin and metalloprotease 10, stromal interaction molecule 1

CLC Number:

R542.2

Figures/Tables 5

References 22

[1]	ZHANG H, JING L, ZHAI C, et al. Intestinal flora metabolite trimethylamine oxide is inextricably linked to coronary heart disease[J]. J Cardiovasc Pharmacol, 2023, 81(3):175-182. doi:10.1097/FJC.0000000000001387.
[2]	ZHU W, LI X. Liquid biopsy in coronary heart disease[J]. Methods Mol Biol, 2023, 2695(1):279-293. doi:10.1007/978-1-0716-3346-5_19.
[3]	SARASTE A, KNUUTI J. ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromes:recommendations for cardiovascular imaging[J]. Herz, 2020, 45(5):409-420. doi:10.1007/s00059-020-04935-x.
[4]	PARK S S, JUNG J, MINTZ G S, et al. Epicardial adipose tissue thickness is related to plaque composition in coronary artery disease[J]. Diagnostics(Basel), 2022, 12(11):2836. doi:10.3390/diagnostics12112836.
[5]	WANG J N, CAO X J. Targeting ADAM10 in renal diseases[J]. Curr Mol Med, 2023, 23(10):1037-1045. doi:10.2174/1566524023666221020142504.
[6]	ZHANG Q, HE Y, XU H, et al. Modulation of STIM1 by a risk insertion/deletion polymorphism underlying genetics susceptibility to sudden cardiac death originated from coronary artery disease[J]. Forensic Sci Int, 2021, 328(1):111010. doi:10.1016/j.forsciint.2021.111010.
[7]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, 中国医师协会循证专业委员会, 等. 无症状成年人心血管病危险评估中国专家共识[J]. 中华心血管病杂志, 2013, 41(10):820-825.
	Chinese Society of Cardiology, Editorial Committee of Chinese Journal of Cardiology, Evidence-based Medicine Committee of Chinese Medical Doctor Association, et al. Chinese expert consensus on cardiovascular disease risk assessment inasymptomatic adults[J]. Chin J Cardiol, 2013, 41(10):820-825. doi:10.3760/cma.j.issn.0253-3758.2013.10.003.
[8]	NAVAS-ACIEN A, DOMINGO-RELLOSO A, SUBEDI P, et al. Blood DNA methylation and incident coronary heart disease:evidence from the strong heart study[J]. JAMA Cardiol, 2021, 6(11):1237-1246. doi:10.1001/jamacardio.2021.2704.
[9]	XIA Y, BREWER A, BELL J T. DNA methylation signatures of incident coronary heart disease:findings from epigenome-wide association studies[J]. Clin Epigenetics, 2021, 13(1):186. doi:10.1186/s13148-021-01175-6.
[10]	KATTA N, LOETHEN T, LAVIE C J, et al. Obesity and coronary heart disease:epidemiology,pathology,and coronary artery imaging[J]. Curr Probl Cardiol, 2021, 46(3):100655. doi:10.1016/j.cpcardiol.2020.100655.
[11]	LEO S, TREMOLI E, FERRONI L, et al. Role of epicardial adipose tissue secretome on cardiovascular diseases[J]. Biomedicines, 2023, 11(6):1653. doi:10.3390/biomedicines11061653.
[12]	BRAESCU L, STURZA A, ABUREL O M, et al. Assessing the relationship between indexed epicardial adipose tissue thickness,oxidative stress in adipocytes,and coronary artery disease complexity in open-heart surgery patients[J]. Medicina(Kaunas), 2024, 60(1):177. doi:10.3390/medicina60010177.
[13]	WANG Q, CHI J, WANG C, et al. Epicardial adipose tissue in patients with coronary artery disease:a meta-analysis[J]. J Cardiovasc Dev Dis, 2022, 9(8):253. doi:10.3390/jcdd9080253.
[14]	QIAN C, SUN Y, JIANG J. Diagnostic values of epicardial adipose tissue thickness with right common carotid artery elasticity and intima-media thickness for middle-aged and elderly patients with coronary heart disease[J]. Int J Gen Med, 2021, 14(1):633-639. doi:10.2147/IJGM.S292426.
[15]	HARRISON N, KOO C Z, TOMLINSON M G. Regulation of ADAM10 by the tspanc8 family of tetraspanins and their therapeutic potential[J]. Int J Mol Sci, 2021, 22(13):6707. doi:10.3390/ijms22136707.
[16]	MAAS S L, DONNERS M M P C, VAN DER VORST E P C. ADAM10 and ADAM17,major regulators of chronic kidney disease induced atherosclerosis[J]. Int J Mol Sci, 2023, 24(8):7309. doi:10.3390/ijms24087309.
[17]	李洪峰, 李敏, 吴亚, 等. 血清MMP9、ADAM10联合对类风湿关节炎患者颈动脉粥样硬化的诊断价值[J]. 标记免疫分析与临床, 2023, 30(8):1393-1397,1430.
	LI H F, LI M, WU Y, et al. The diagnostic value of serum MMP9 and ADAM10 in patients with rheumatoid arthritis[J]. Lab Immun Clin Med, 2023, 30(8):1393-1397,1430. doi:10.11748/bjmy.issn.1006-1703.2023.08.024.
[18]	赵茜, 杜思成, 高宇, 等. 血清ADAM10与2型糖尿病、冠状动脉粥样硬化的相关性研究[J]. 医学研究杂志, 2020, 49(12):49-52,56.
	ZHAO Q, DU S C, GAO Y, et al. Study on the correlation between serum ADAM10 and type 2 diabetes mellitus and coronary atherosclerosis[J]. Journal of Medical Research, 2020, 49(12):49-52,56. doi:10.11969/j.issn.1673-548X.2020.12.013.
[19]	LU T, ZHANG Y, SU Y, et al. Role of store-operated Ca²⁺ entry in cardiovascular disease[J]. Cell Commun Signal, 2022, 20(1):33. doi:10.1186/s12964-022-00829-z.
[20]	BERNA-ERRO A, SANCHEZ-COLLADO J, NIETO-FELIPE J, et al. The Ca²⁺ sensor stim in human diseases[J]. Biomolecules, 2023, 13(9):1284. doi:10.3390/biom1309128.
[21]	MA G, BI S, ZHANG P. Long non-coding RNA MIAT regulates ox-LDL-induced cell proliferation,migration and invasion by miR-641/STIM1 axis in human vascular smooth muscle cells[J]. BMC Cardiovasc Disord, 2021, 2(1):248. doi:10.1186/s12872-021-02048.
[22]	郑荣, 南京柱, 高艳红. UA、TG、LDL-C、Plip对冠心病二级预防降脂治疗患者的危险因素研究[J]. 标记免疫分析与临床, 2021, 28(10):1770-1775.
	ZHENG R, NAN J Z, GAO Y H. Study on risk factors of UA,TG,LDL-C and Plip in patients with coronary heart disease after secondary prevention and lipid-lowering therapy[J]. Lab Immun Clin Med, 2021, 28(10):1770-1775. doi:10.11748/bjmy.issn.1006-1703.2021.10.029.

组别	n		年龄/ 岁		性别（男/女）		BMI/ （kg/m²）	高血压		糖尿病		吸烟史		酗酒史		TG/（mmol/L）		TC/（mmol/L）
对照组	100		58.67±6.11		53/47		22.65±2.36	67（67.00）		35（35.00）		31（31.00）		43（43.00）		1.52±0.17		4.58±0.95
研究组	119		59.78±6.15		64/55		22.59±2.37	75（63.03）		46（38.66）		39（32.77）		52（43.70）		2.29±0.25		4.67±1.09
t或χ²			1.336		0.013		0.187	0.377		0.312		0.079		0.011		25.254^＊		0.641
组别		LDL-C/ （mmol/L）		HDL-C/ （mmol/L）		收缩压/ mmHg			舒张压/ mmHg		CRP/ （mg/L）		血Cr/（μmol/L）		Fib/ （g/L）		UA/ （μmol/L）
对照组		2.75±0.32		1.15±0.26		136.58±16.35			83.95±9.68		22.85±3.93		65.45±17.33		3.19±0.61		351.96±65.27
研究组		3.55±0.73		1.12±0.23		135.47±15.85			81.71±9.37		23.16±4.01		68.54±16.62		3.15±0.55		358.65±65.33
t或χ²		10.746^＊		0.656		0.509			1.733		0.575		1.344		0.507		0.754

组别	n		年龄/ 岁		性别（男/女）		BMI/ （kg/m²）	高血压		糖尿病		吸烟史		酗酒史		TG/（mmol/L）		TC/（mmol/L）
对照组	100		58.67±6.11		53/47		22.65±2.36	67（67.00）		35（35.00）		31（31.00）		43（43.00）		1.52±0.17		4.58±0.95
研究组	119		59.78±6.15		64/55		22.59±2.37	75（63.03）		46（38.66）		39（32.77）		52（43.70）		2.29±0.25		4.67±1.09
t或χ²			1.336		0.013		0.187	0.377		0.312		0.079		0.011		25.254^＊		0.641
组别		LDL-C/ （mmol/L）		HDL-C/ （mmol/L）		收缩压/ mmHg			舒张压/ mmHg		CRP/ （mg/L）		血Cr/（μmol/L）		Fib/ （g/L）		UA/ （μmol/L）
对照组		2.75±0.32		1.15±0.26		136.58±16.35			83.95±9.68		22.85±3.93		65.45±17.33		3.19±0.61		351.96±65.27
研究组		3.55±0.73		1.12±0.23		135.47±15.85			81.71±9.37		23.16±4.01		68.54±16.62		3.15±0.55		358.65±65.33
t或χ²		10.746^＊		0.656		0.509			1.733		0.575		1.344		0.507		0.754

组别	n	EAT厚度/mm	ADAM10/（ng/L）	STIM1/（ng/L）
对照组	100	5.67±0.93	1 893.42±398.47	37.52±7.85
研究组	119	6.84±1.25	2 327.60±465.73	46.14±8.91
t		7.963^＊	7.335^＊	7.530^＊

组别	n	EAT厚度/mm	ADAM10/（ng/L）	STIM1/（ng/L）
对照组	100	5.67±0.93	1 893.42±398.47	37.52±7.85
研究组	119	6.84±1.25	2 327.60±465.73	46.14±8.91
t		7.963^＊	7.335^＊	7.530^＊

变量	β	SE	Wald χ²	P	OR	OR 95%CI
EAT厚度	0.618	0.239	6.695	0.010	1.856	1.162~2.965
ADAM10	0.493	0.213	5.354	0.021	1.637	1.078~2.485
STIM1	0.763	0.315	5.869	0.015	2.145	1.157~3.978
TG	0.707	0.285	6.146	0.013	2.027	1.159~3.544
LDL-C	0.498	0.216	5.310	0.021	1.645	1.077~2.512
常数项	-23.854	2.762	58.213	<0.001	0.000